Global Bipolar Disorders and Treatment
Market Report
2025
Bipolar Disorders and Treatment Market Report 2025 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
|
Rating: 4.8 | Review: 5
Share your contact details to receive free updated sample copy/pages of the recently published edition of Bipolar Disorders and Treatment Market Report 2024.
Global Bipolar Disorders and Treatment Market Report 2024 Market Size Split by Drug Class (Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, Anti-Anxiety Drugs), by Distri...
According to Cognitive Market Research, The Bipolar Disorder Treatment Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Europe region is the fastest growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Asia Pacific accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Bipolar Disorder Treatment Market held the highest market revenue share in 2024.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Drug Class |
|
| Market Split by Distribution Channel |
|
| Market Split by Bipolar Disorder |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Bipolar Disorders and Treatment industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Bipolar Disorders and Treatment Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Bipolar Disorders and Treatment Market Report Description
Introduction of The Bipolar Disorder Treatment Market
Bipolar disorder (formerly called manic-depressive illness or manic depression) is a mental illness that causes unusual shifts in a person's mood, energy, activity levels, and concentration. These shifts can make it difficult to carry out day-to-day tasks. There are three types of bipolar disorder. All three types involve clear changes in mood, energy, and activity levels. These moods range from periods of extremely “up,” elated, irritable, or energized behavior (known as manic episodes) to very “down,” sad, indifferent, or hopeless periods (known as depressive episodes). Less severe manic periods are known as hypomanic episodes.
Bipolar I disorder is defined by manic episodes that last for at least 7 days (nearly every day for most of the day) or by manic symptoms that are so severe that the person needs immediate medical care. Usually, depressive episodes occur as well, typically lasting at least 2 weeks. Episodes of depression with mixed features (having depressive symptoms and manic symptoms at the same time) are also possible. Experiencing four or more episodes of mania or depression within 1 year is called “rapid cycling.”
Bipolar II disorder is defined by a pattern of depressive episodes and hypomanic episodes. The hypomanic episodes are less severe than the manic episodes in bipolar I disorder.
Cyclothymic disorder (also called cyclothymia) is defined by recurring hypomanic and depressive symptoms that are not intense enough or do not last long enough to qualify as hypomanic or depressive episodes.
The growing incidence of bipolar illness, government initiatives, the development of the healthcare infrastructure, and the rising popularity of sedentary lifestyles are all contributing factors to the rise observed throughout the predicted period. Personalized treatment strategies, the integration of digital health, novel drugs, preventative measures, neuroimaging, and biomarkers are key themes for the predicted period.
Bipolar Disorders and Treatment Market Size
Market Dynamics of The Bipolar Disorder Treatment Market
Key Drivers for The Bipolar Disorder Treatment Market
- The increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder Market.
The market for treatments for bipolar disorder is anticipated to rise in the future due to the rising incidence of the condition. Bipolar disorder is becoming more common due to several risk factors, including drug addiction, excessive levels of stress, and others. People with bipolar disorder frequently experience depression, and the condition typically manifests in their late teens or early 20s. Men and women are equally likely to be afflicted by bipolar illness. Thus, an increase in the number of instances of bipolar conditions and the growing need to treat them successfully would grow the market for bipolar disorder treatment.
For instance, according to the Depression and Bipolar Support Alliance, a US-based non-profit association providing support to patients of depression or bipolar disorder, in 2021, approximately 5.7 million adult Americans which was about 2.6% of the U.S. population were affected by bipolar disorder. The median age of the onset of bipolar disorder is 25 years, and more than two-thirds of people suffering from bipolar disorder had at least one relative with the illness. Therefore, the increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder therapeutics market.
Source:(https://www.dbsalliance.org/education/bipolar-disorder/bipolar-disorder-statistics/)
Thus The rising prevalence of bipolar disorder underscores the importance of timely identification and appropriate care. With symptoms impacting daily functioning, effective treatments are essential for managing the condition and improving quality of life.
- Immediate approval of bipolar disorder therapeutics by regulatory authorities drives the bipolar disorder market.
The immediate approval of bipolar disorder therapeutics treatment by regulatory bodies is raising the demand for bipolar disorder therapy. The key market players are concentrating on obtaining product approvals from regulatory authorities, which is expected to drive the bipolar disorder treatment market over the forecast period. This is because they want to treat adults with schizophrenia and use it as an adjuvant therapy to lithium or valproate for the maintenance treatment of bipolar disorder in adults.
For instance, in January 2023, Luye Pharma Group, an international pharmaceutical company, announced it had received FDA approval for its Rykindo (risperidone), which is an extended-release injectable suspension administered via intramuscular injection once every two weeks.
Source:(https://www.luye.cn/lvye_en/view.php?id=2140#:~:text=PRINCETON%2C%20N.J.%2C%20January%2015%2C,risperidone)%20for%20extended%2Drelease%20injectable)
For instance, in September 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck announced that the U.S. FDA had approved their new drug application (NDA) for a 2-month medication for schizophrenia and bipolar disorder I in adults. It is called ‘aripiprazole’.
Source:(https://www.otsuka-us.com/news/otsuka-and-lundbeck-announce-us-fda-acceptance-new-drug-application-aripiprazole-2-month-ready)
Restraint Factor for The Bipolar Disorder Treatment Market
- Side effects associated with drugs restrain the bipolar disorder market.
The lithium (Li) element utilized to make anti-mania medications has the potential to overdose and cause anorexia. Furthermore, as several investigations have indicated, long-term lithium usage might harm the effects of the hormone vasopressin, which can lead to insipid diabetes. This strategy may also limit how widely available over-the-counter bipolar medications are for treating the disease.
Since the age range in which bipolar illness symptoms often manifest is between 20 and 25 years old, parents frequently ignore this fact. This impairs the efficacy of natural bipolar medications, slows down the lengthy process for treating bipolar diseases, and lowers the drug's market value. Many generic drugs have entered the market over the years, challenging the well-established supply networks of over-the-counter mood stabilizers.
Another significant issue with individuals using these kinds of medicines for bipolar therapy is the possibility of drug addiction. The small number of anticonvulsant medications that are authorized for use as over-the-counter treatments for bipolar illness may potentially be a hindrance to the market's explosive expansion worldwide.
For instance, some of the medications including carbamazepine, Divalproex sodium, and Lithium used in the treatment of bipolar disorder have some side effects such as nausea, tremors, sexual problem, impaired memory, muscle weakness, decreased thyroid function, liver and kidney damage, skin reactions, and others.
Source:( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5164879/)
Hence side effects associated with bipolar medications pose challenges to treatment accessibility and market expansion. Issues like potential overdosing, hormonal impacts, and addiction risks highlight the need for safer and more widely available treatment options for bipolar disorder.
How did COVID-19 impact The Bipolar Disorder Treatment Market
The World Health Organization issued a public health emergency on January 30, 2020, following the spread of the COVID-19 virus epidemic to over 100 nations worldwide in December 2019. The three primary ways that COVID-19 impacted the economy were through its direct effects on drug supply and demand, its disruption of medication delivery systems, and its financial effects on businesses and financial markets. Lockdowns across the nation have caused issues for drug trafficking in several nations, including Egypt, Saudi Arabia, China, India, and the United Arab Emirates. Nonetheless, the global market for bipolar illness treatments was somewhat negatively impacted by the COVID-19 pandemic.
For instance, in September 2021, an article published by the Nations Institute of Health (NIH) titled Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review’, focused on how the clinical course of bipolar disorder (BD) is affected by social isolation, stifling rules, lifestyle changes, and biological circadian rhythm abnormalities brought on by the COVID-19 pandemic, or infection-related worries. According to several research, persons with bipolar disorder (BD) experienced fewer relapses or symptoms that worsened during the pandemic, or less severe psychiatric symptoms and greater feelings of well-being than they had before the pandemic. Patients with bipolar disorder (BD) showed less psychological discomfort than those with major depressive disorder (MDD).
Source:(https://pubmed.ncbi.nlm.nih.gov/34517248/)
For instance, in December 2020, NeuroRx, Inc., a clinical-stage, small molecule pharmaceutical company, and Big Rock Partners Acquisition Corp., a special purpose acquisition company, entered into an agreement and plan of merger to increase the development of novel therapeutics for the treatment of COVID-19 and Bipolar Depression.
Source:(https://www.sec.gov/Archives/edgar/data/1719406/000165495420013699/brpa_ex991.htm)
Opportunities for The Bipolar Disorder Treatment Market
The development of innovative bipolar disorder treatments represents a significant opportunity for the automotive industry.
To address the needs of a wider customer base, boost sales, and boost income, major firms in the bipolar disorder therapeutics and related industry are creating novel treatments for depressive episodes linked to bipolar I or II disease. Bipolar depression is the most common and severe clinical symptom of bipolar illness. These depressive episodes are associated with a worse prognosis, longer duration, and more recurrences than manic/hypomanic episodes.
For instance, in December 2021, Intra-Cellular Therapies, Inc. (ITCI), a US-based biopharmaceutical company, discovered and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders, announced U.S FDA approved ‘CAPLYTA’ medication in treating the depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-positive-phase-3-topline)
For instance, in December 2021, Zydus Cadila, a pharmaceutical company, gets the U.S. Food and Drug Administration (U.S. FDA) approval to market the generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.
Source:(https://zyduslife.com/public/pdf/pressrelease/Press-Release-Zydus-receives-final-approval-and-180-days-shared-exclusivity-from-the-USFDA-for-Cariprazine-Capsules-12-09-22.pdf)
For instance, in December 2021, Intra-Cellular Therapies, Inc. announced that the United States Food and Drug Administration (FDA) approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar)
However Innovative treatments targeting depressive episodes in bipolar disorder are being developed to meet the diverse needs of patients. With depressive episodes posing significant challenges, advancements in treatment aim to improve outcomes and prognosis for individuals with bipolar I or II disorder.
We have various report editions of Bipolar Disorders and Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: The Bipolar Disorder Treatment Market
The bipolar disorder market is highly competitive and somewhat fragmented worldwide. To stay afloat in the industry, the major businesses functioning in it regularly use different development methods. These major competitors use a variety of growth methods to survive in the cutthroat industry, including product launches, inventions, mergers and acquisitions, partnerships and collaborations, and extensive research and development. The major market players are also always concentrating on research and development to provide the most economical and effective solutions to industries.
For instance, in June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, acquired the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd for an undisclosed amount. The acquisition enables Neuraxpharm Group to expand its therapeutic product portfolio in Greece and Europe. This agreement aims to extend Neuraxpharm's reach in Greece and harness its deep expertise in the central nervous system (CNS) to offer the right products from its extensive lineup to CNS patients, healthcare professionals, pharmacists, and hospitals across Greece, effectively meeting the healthcare demands of patients in the country. Lyofin Ltd. is a Greece-based pharmaceutical company.
Source:(https://www.neuraxpharm.com/media/neuraxpharm-expands-greek-product-portfolio-with-acquisition-of-lazap-a-well-established-antipsychotic-brand)
Top Companies Market Share in Bipolar Disorders and Treatment Industry: (In no particular order of Rank)
- Allergan
- AstraZeneca plc
- Bristol Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc
- H. Lundbeck A/S
- Janssen Pharmaceuticals Inc.
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Sunovion Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Abbott Laboratories
- Novartis International AG
- Alkermes plc
- AbbVie Inc.
- Merck & Co. Inc.
- Mylan N.V.
- Neurocrine Biosciences Inc.
- Vanda Pharmaceuticals Inc.
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of The Bipolar Disorder Treatment Market
Which Region Will Dominate the Market in 2024?
According to Cognitive Research, the North America region dominated the market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future Due to the rise in bipolar disorder instances and the improved healthcare system, the market is anticipated to increase rapidly over the projected decade. The National Alliance on Mental Illness reports that around one in five individuals in the country will suffer from mental illness at some point in their lifetime. When manic or depressive episodes are severe, individuals must be admitted to the hospital to keep them from hurting themselves or other people. A manic episode severe enough to need emergency hospitalization is one of the hallmarks of bipolar I illness, according to the NIMH. Bipolar disorder treatment is in high demand due to the growing prevalence of the condition; as a result, growth in the market is anticipated throughout the projected decade. Increased market growth is anticipated in the region when goods are approved by the US Food and Drug Administration (USFDA).
For instance, in April 2022, the United States Food and Drug Administration has approved a new drug “IGALMI” from BioXcel used to treat patients with schizophrenia or bipolar I or II disorder.
Source:(https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-fda-approval-igalmitm#:~:text=%E2%80%9CIGALMI%20is%20the%20first%20new,.%2C%20CEO%20of%20BioXcel%20Therapeutics.)
For instance, in May 2021, Alembic Pharmaceuticals got United States Food and Drug Administration (USFDA) approval for bipolar depression drug - Lurasidone Hydrochloride tablets, used to treat bipolar depression.
Source:(https://timesofindia.indiatimes.com/alembic-pharma-gets-usfda-nod-for-bipolar-depression-drug/articleshow/82627352.cms)
Which Region Is Expanding at The Fastest CAGR?
Europe's market share is the second-largest in the world. In the European region, the bipolar disorder treatment market reflects a blend of established healthcare systems and varying degrees of access to mental health services across countries. Nations such as Germany, France, and the UK benefit from robust healthcare infrastructure, leading to higher diagnosis rates and widespread adoption of pharmacological and psychosocial interventions. Moreover, advancements in research and development, coupled with favorable reimbursement policies, drive the introduction of novel treatment options and therapeutic approaches. Conversely, Eastern European countries encounter challenges related to resource constraints, stigma, and limited access to specialized care, resulting in disparities in diagnosis and treatment. Nevertheless, initiatives aimed at raising awareness, improving mental health literacy, and integrating mental health services into primary care are gradually addressing these disparities and fostering market growth across the European region. Collaboration between public and private sectors, along with investment in mental health initiatives, is poised to further enhance the landscape for bipolar disorder treatment in Europe.
For instance, SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, is marking World Bipolar Day 2024 by announcing the launch of a revolutionary test for the diagnosis of bipolar disorder in France.
The current report Scope analyzes Bipolar Disorders and Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Bipolar Disorders and Treatment Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Bipolar Disorders and Treatment Market Analysis
Global Bipolar Disorders and Treatment Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Bipolar Disorders and Treatment Industry growth. Bipolar Disorders and Treatment market has been segmented with the help of its Drug Class, Distribution Channel Bipolar Disorder, and others. Bipolar Disorders and Treatment market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Segment Performance in The Bipolar Disorder Treatment Market
Drug Class Segment Analysis
The anti-psychotic Drugs segment holds the largest market share. This is due to the increasing prevalence of bipolar disorder. Antipsychotic medications were originally utilized in psychiatric therapy to treat acute episodes of bipolar illness and prevent relapses. The effectiveness of this family of medications to treat manic depression has drawn renewed attention with the introduction of second-generation antipsychotics, increasing their market share. Anti-psychotics are commonly used as maintenance therapy to prevent relapses and stabilize mood fluctuations in both Bipolar I and Bipolar II disorders. Their efficacy in managing a broad spectrum of symptoms makes them indispensable in the treatment landscape. Moreover, ongoing research and development efforts have led to the introduction of newer-generation anti-psychotics with improved tolerability and fewer side effects, further driving their adoption. Overall, the widespread use, effectiveness across symptom domains, and continuous innovation in anti-psychotic medications solidify their position as the leading segment in the bipolar disorder market.
For instance, in December 2021, Zydus Cadila got the United States Food and Drug Administration (USFDA) approval to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.
Source:(https://www.business-standard.com/article/companies/zydus-cadila-gets-usfda-approval-to-market-generic-schizophrenia-drug-121121100071_1.html)
Bipolar Disorders and Treatment Market Share (%) by Drug Class in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Bipolar Disorders and Treatment Industry. Request a Free Sample PDF!
Distribution Channel Segment Analysis
Hospitals hold the largest market share Hospital segment dominated the Bipolar Disorder Treatment Market as there will be more product introductions for the treatment of bipolar illness throughout the projected period. This market has grown as a result of growing hospitalization rates and increased worldwide awareness of mental health issues. Prescription medications needed for both therapeutic and symptomatic relief are available to patients in institutions. Furthermore, the market is anticipated to grow throughout the projection period due to improved pharmaceutical accessibility with access to sufficient distribution networks.
For instance, Antipsychotic medications are commonly used in hospitals for the management of patients with delirium. Delirium occurs in 30%–50% of adults aged 65 years or older admitted to the hospital and may be hypoactive (lethargy, reduced psychomotor functioning), hyperactive (agitation, hallucinations), or mixed.1 Twenty-nine percent of patients with delirium admitted to hospital in the United States are newly started on antipsychotic medications
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426344/)
Thus rising incidence of Bipolar Disorder Treatment disease, increased treatment rates, higher awareness and diagnosis, and a large number of hospitals offering patient care are contributing to an increase in the number of patients treated. To treat Bipolar Disorder Treatment, hospitals are adopting immunotherapies and chemotherapies.
Bipolar Disorders and Treatment Market Share (%) by Distribution Channel in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Bipolar Disorders and Treatment Bipolar Disorder Segment Analysis
Bipolar Disorder Segment Analysis
The Bipolar I disorder segment is anticipated to maintain a significant global market share within the bipolar disorder market due to several key factors. Bipolar I disorder represents the most severe form of the condition, characterized by manic episodes often accompanied by depressive episodes. These severe mood swings necessitate intensive and ongoing treatment, including medication management and therapy, driving demand for therapeutic interventions. Additionally, Bipolar I disorder typically requires more extensive medical intervention and hospitalization compared to other subtypes, further contributing to market growth. Moreover, the increasing prevalence of Bipolar I disorder, influenced by factors such as genetic predisposition, environmental stressors, and changing diagnostic criteria, ensures a steady market base. Furthermore, ongoing research and development efforts focused on innovative treatments targeting manic and depressive episodes specific to Bipolar I disorder are expected to bolster market expansion.
For the treatment of bipolar I disorder among adults, Alkermes PLC developed a treatment drug by the name of LYBALVITM which is a combination of olanzapine and samidorphan. It received the approval of the US Food and Drug Administration (FDA) in June 2021, which will make it available as an over-the-counter medicine for bipolar treatment.
Source:(https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-approval-lybalvitm-treatment)
For instance, in February 2024, According to the National Comorbidity Survey Replication study, which uses a broad definition of bipolar, an estimated 4.4% of U.S. adults experienced bipolar spectrum disorders at some time in their lives.
Source:( https://news.vumc.org/2024/02/08/new-algorithms-show-promise-for-predicting-bipolar-disorder-risk/#:~:text=According%20to%20the%20National%20Comorbidity,some%20time%20in%20their%20lives.)
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Bio :
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
With the help of the above study about the Bipolar Disorder Treatment Market, it can be concluded that the market for Bipolar Disorder Treatment worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions
Bipolar Disorders and Treatmentmarket size and its growth rate has been provided in the report. The historical period included in the report is from 2019 to 2023, whereas, the report provides forecast data for the years 2024 to 2031. This will help you to in terms of global market share, regional market share, country level market share to understand how the market has been performing in the past and how it is going to perform in the following years. Correspondingly, historical and forecast analysis comprises sales and revenue data of the global Bipolar Disorders and Treatmentmarket. Market size for UK, Europe, North America, Asia Pacific, Middle East & Africa is also included in the report.
The major factors affecting the Bipolar Disorders and Treatment market in a positive, as well as negative perspective, have been provided with detailed analysis in the report. This segment has encompassed drivers, opportunities, and challenges faced by the industry. This will help you to understand the major factors impacting Bipolar Disorders and Treatment market trends and develop your business strategy accordingly.
Major manufacturers or list of Bipolar Disorders and Treatment manufacturers 2024 involved in the market have been profiled in the report along with their business strategies, recent developments, SWOT analysis, business overview, and market Trend from the year 2019-2023. Bipolar Disorders and Treatment Companies such as Allergan, AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc. are part of the final deliverable document along with the same we can provide data for 2nd, 3rd, start-up level companies data and strategies as well. This will help you to understand the competitive analysis of the market and how other players are performing in the market. This detailed competitive analysis will help you to strategize your business accordingly and will keep you one step ahead. A quantitative and qualitative analysis of the main players in the Bipolar Disorders and Treatment market is introduced, from the perspective of sales, revenue and price.
Under Bipolar Disorders and Treatment market segments analysis Drug Class, Distribution Channel, Bipolar Disorder. It provides detailed insights on each type and application. Further, it provides which sub-segment is dominating the Bipolar Disorders and Treatment market along with its reason. Additionally, the Bipolar Disorders and Treatment market report will help you to analyze which sub-segment is fastest-growing during the forecast period.
After the analysis of the complete market, the report has provided how the COVID-19 pandemic has affected the market. All the parameters have covered the overall impact of COVID -19 on the market value, market trend & growth of the market, and how the major players in the particular market are adopting these changes. This will help you to understand the overall optimistic, pessimistic, and neutral effects of the coronavirus pandemic on the Bipolar Disorders and Treatment market.
The Bipolar Disorders and Treatment market has been analyzed thoroughly and has estimated the parameters which have affected the market in the historical period as well as how the market is going to perform in the following years. This will provide a complete market scenario and help you to strategize your next move accordingly to the Bipolar Disorders and Treatment market Share.
The report gives an exhaustive investigation of the Bipolar Disorders and Treatment market at country & regional levels, and provides an analysis of the industry trends in each of the regions, from sales, revenue, and consumption. It will help you to understand which region is dominating the market and is expected to grow significantly in the following years. The regional analysis will help you in strategizing the expansion of business.
Bipolar Disorders and Treatmentmarket report has provided PESTEL and Porter analysis to provide insightful information regarding the market scenario. It also provides market attractiveness analysis with an acknowledgment of various factors within the market, including growth rate and market size, as well as outside factors such as access to raw materials, competition, and industry capacity.
The sample report for the Bipolar Disorders and Treatment Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Bipolar Disorders and Treatment Market
In January 2022, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the antipsychotic Caplyta (lumateperone) for the treatment of bipolar I and II depression in adults. Caplyta, marketed by Intra-Cellular Therapies Inc., was already approved for the treatment of schizophrenia in adults.
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar)
In September 2022, Otsuka America Pharmaceutical, Inc., (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. FDA approved their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults. This approval helped the company to expand its customer base.
Source:(https://www.otsuka-us.com/news/otsuka-and-lundbeck-announce-us-fda-acceptance-new-drug-application-aripiprazole-2-month-ready)
In December 2021, Intra-Cellular Therapies, Inc. confirmed that the U.S. FDA had approved CAPLYTA to treat depressive episodes linked with bipolar I or II disorder in adults, such as monotherapy and adjunctive therapy with valproate or lithium.
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar)
Fanapt (iloperidone) from Vanda Pharmaceuticals has received FDA approval for the acute management of manic or mixed episodes linked to adult bipolar I illness. Based on the outcomes of a Phase III clinical trial with 400 patients enrolled, the approval was granted. With significant gains evident after two weeks of treatment, the primary goal of a higher success rate than placebo was reached after four weeks. Vanda said that the expanded indication for Fanapt, which was first licenced in 2009 to treat patients with schizophrenia, will give patients variable dosage and a well-established safety profile. In the US, bipolar disorder affects approximately 5.7 million adults, with a 25-year typical onset age. Bipolar disorder may run in families because most persons who are diagnosed with it have a family member who also has the illness or who suffers from severe depression. With this FDA approval, bipolar I disorder management options for patients and service providers are expanded. Based on encouraging findings from two placebo-controlled Phase III clinical trials comparing the medication to active control and placebo in schizophrenia patients, Vanda Pharmaceuticals approved Fanapt for treatment in 2009. Before overturning its earlier judgement, the FDA had denied Vanda's New Drug Application for Fanapt nearly a year earlier.
Source Link: https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/us-fda-approves-vandas-drug-for-treatment-of-bipolar-disorder/108988688?utm_source=most_read&utm_medium=newsDetail
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Bipolar Disorders and Treatment Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Drug Class | Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, Anti-Anxiety Drugs |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| Bipolar Disorder | Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder |
| List of Competitors | Allergan, AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc. |
Expand All
This chapter will help you gain GLOBAL Market Analysis of Bipolar Disorders and Treatment. Further deep in this chapter, you will be able to review Global Bipolar Disorders and Treatment Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Bipolar Disorders and Treatment Revenue Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Bipolar Disorders and Treatment Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Bipolar Disorders and Treatment Revenue Market Size By Region
-
-
1.3 Global Bipolar Disorders and Treatment Market Size By Drug Class 2019 -2031
-
1.3.1 Mood Stabilizer Market Size
-
1.3.2 Anticonvulsants Market Size
-
1.3.3 Anti-Psychotic Drugs Market Size
-
1.3.4 Anti-Depressant Drugs Market Size
-
1.3.5 Anti-Anxiety Drugs Market Size
-
-
1.4 Global Bipolar Disorders and Treatment Market Size By Distribution Channel 2019 -2031
-
1.4.1 Hospital Pharmacies Market Size
-
1.4.2 Retail Pharmacies Market Size
-
1.4.3 Online Pharmacies Market Size
-
-
1.5 Global Bipolar Disorders and Treatment Market Size By Bipolar Disorder 2019 -2031
-
1.5.1 Bipolar I Disorder Market Size
-
1.5.2 Bipolar II Disorder Market Size
-
1.5.3 Cyclothymic Disorder Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Drug Class
-
1.7.3 Global Market Revenue Split By Distribution Channel
-
1.7.4 Global Market Revenue Split By Bipolar Disorder
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Bipolar Disorders and Treatment. Further deep in this chapter, you will be able to review North America Bipolar Disorders and Treatment Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Bipolar Disorders and Treatment Market Size 2019 - 2031
-
2.1.1 North America Bipolar Disorders and Treatment Market Size By Country 2019 - 2031
-
2.1.2 North America Bipolar Disorders and Treatment Market Size by Drug Class 2019 -2031
-
2.1.2.1 North America Mood Stabilizer Market Size
-
2.1.2.2 North America Anticonvulsants Market Size
-
2.1.2.3 North America Anti-Psychotic Drugs Market Size
-
2.1.2.4 North America Anti-Depressant Drugs Market Size
-
2.1.2.5 North America Anti-Anxiety Drugs Market Size
-
-
2.1.3 North America Bipolar Disorders and Treatment Market Size by Distribution Channel 2019 -2031
-
2.1.3.1 North America Hospital Pharmacies Market Size
-
2.1.3.2 North America Retail Pharmacies Market Size
-
2.1.3.3 North America Online Pharmacies Market Size
-
-
2.1.4 North America Bipolar Disorders and Treatment Market Size by Bipolar Disorder 2019 -2031
-
2.1.4.1 North America Bipolar I Disorder Market Size
-
2.1.4.2 North America Bipolar II Disorder Market Size
-
2.1.4.3 North America Cyclothymic Disorder Market Size
-
-
This chapter will help you gain Europe Market Analysis of Bipolar Disorders and Treatment. Further deep in this chapter, you will be able to review Europe Bipolar Disorders and Treatment Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Bipolar Disorders and Treatment Market Size 2019 - 2031
-
3.1.1 Europe Bipolar Disorders and Treatment Market Size By Country 2019 - 2031
-
3.1.2 Europe Bipolar Disorders and Treatment Market Size by Drug Class 2019 -2031
-
3.1.2.1 Europe Mood Stabilizer Market Size
-
3.1.2.2 Europe Anticonvulsants Market Size
-
3.1.2.3 Europe Anti-Psychotic Drugs Market Size
-
3.1.2.4 Europe Anti-Depressant Drugs Market Size
-
3.1.2.5 Europe Anti-Anxiety Drugs Market Size
-
-
3.1.3 Europe Bipolar Disorders and Treatment Market Size by Distribution Channel 2019 -2031
-
3.1.3.1 Europe Hospital Pharmacies Market Size
-
3.1.3.2 Europe Retail Pharmacies Market Size
-
3.1.3.3 Europe Online Pharmacies Market Size
-
-
3.1.4 Europe Bipolar Disorders and Treatment Market Size by Bipolar Disorder 2019 -2031
-
3.1.4.1 Europe Bipolar I Disorder Market Size
-
3.1.4.2 Europe Bipolar II Disorder Market Size
-
3.1.4.3 Europe Cyclothymic Disorder Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of Bipolar Disorders and Treatment. Further deep in this chapter, you will be able to review Asia Pacific Bipolar Disorders and Treatment Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Bipolar Disorders and Treatment Market Size 2019 - 2031
-
4.1.1 Asia Pacific Bipolar Disorders and Treatment Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Bipolar Disorders and Treatment Market Size by Drug Class 2019 -2031
-
4.1.2.1 Asia Pacific Mood Stabilizer Market Size
-
4.1.2.2 Asia Pacific Anticonvulsants Market Size
-
4.1.2.3 Asia Pacific Anti-Psychotic Drugs Market Size
-
4.1.2.4 Asia Pacific Anti-Depressant Drugs Market Size
-
4.1.2.5 Asia Pacific Anti-Anxiety Drugs Market Size
-
-
4.1.3 Asia Pacific Bipolar Disorders and Treatment Market Size by Distribution Channel 2019 -2031
-
4.1.3.1 Asia Pacific Hospital Pharmacies Market Size
-
4.1.3.2 Asia Pacific Retail Pharmacies Market Size
-
4.1.3.3 Asia Pacific Online Pharmacies Market Size
-
-
4.1.4 Asia Pacific Bipolar Disorders and Treatment Market Size by Bipolar Disorder 2019 -2031
-
4.1.4.1 Asia Pacific Bipolar I Disorder Market Size
-
4.1.4.2 Asia Pacific Bipolar II Disorder Market Size
-
4.1.4.3 Asia Pacific Cyclothymic Disorder Market Size
-
-
This chapter will help you gain South America Market Analysis of Bipolar Disorders and Treatment. Further deep in this chapter, you will be able to review South America Bipolar Disorders and Treatment Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Bipolar Disorders and Treatment Market Size 2019 - 2031
-
5.1.1 South America Bipolar Disorders and Treatment Market Size By Country 2019 - 2031
-
5.1.2 South America Bipolar Disorders and Treatment Market Size by Drug Class 2019 -2031
-
5.1.2.1 South America Mood Stabilizer Market Size
-
5.1.2.2 South America Anticonvulsants Market Size
-
5.1.2.3 South America Anti-Psychotic Drugs Market Size
-
5.1.2.4 South America Anti-Depressant Drugs Market Size
-
5.1.2.5 South America Anti-Anxiety Drugs Market Size
-
-
5.1.3 South America Bipolar Disorders and Treatment Market Size by Distribution Channel 2019 -2031
-
5.1.3.1 South America Hospital Pharmacies Market Size
-
5.1.3.2 South America Retail Pharmacies Market Size
-
5.1.3.3 South America Online Pharmacies Market Size
-
-
5.1.4 South America Bipolar Disorders and Treatment Market Size by Bipolar Disorder 2019 -2031
-
5.1.4.1 South America Bipolar I Disorder Market Size
-
5.1.4.2 South America Bipolar II Disorder Market Size
-
5.1.4.3 South America Cyclothymic Disorder Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of Bipolar Disorders and Treatment. Further deep in this chapter, you will be able to review Middle East and Africa Bipolar Disorders and Treatment Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Bipolar Disorders and Treatment Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Bipolar Disorders and Treatment Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Bipolar Disorders and Treatment Market Size by Drug Class 2019 -2031
-
6.1.2.1 Middle East and Africa Mood Stabilizer Market Size
-
6.1.2.2 Middle East and Africa Anticonvulsants Market Size
-
6.1.2.3 Middle East and Africa Anti-Psychotic Drugs Market Size
-
6.1.2.4 Middle East and Africa Anti-Depressant Drugs Market Size
-
6.1.2.5 Middle East and Africa Anti-Anxiety Drugs Market Size
-
-
6.1.3 Middle East and Africa Bipolar Disorders and Treatment Market Size by Distribution Channel 2019 -2031
-
6.1.3.1 Middle East and Africa Hospital Pharmacies Market Size
-
6.1.3.2 Middle East and Africa Retail Pharmacies Market Size
-
6.1.3.3 Middle East and Africa Online Pharmacies Market Size
-
-
6.1.4 Middle East and Africa Bipolar Disorders and Treatment Market Size by Bipolar Disorder 2019 -2031
-
6.1.4.1 Middle East and Africa Bipolar I Disorder Market Size
-
6.1.4.2 Middle East and Africa Bipolar II Disorder Market Size
-
6.1.4.3 Middle East and Africa Cyclothymic Disorder Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Bipolar Disorders and Treatment Market Size by Drug Class 2019 -2031
-
7.1.2 Country 1Bipolar Disorders and Treatment Market Size by Distribution Channel 2019 -2031
-
7.1.3 Country 1Bipolar Disorders and Treatment Market Size by Bipolar Disorder 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of Bipolar Disorders and Treatment. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Bipolar Disorders and Treatment Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Allergan
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 AstraZeneca plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Bristol Myers Squibb Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Eli Lilly and Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 GlaxoSmithKline plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 H. Lundbeck A/S
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Janssen Pharmaceuticals Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Otsuka Holdings Co. Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Pfizer Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Sunovion Pharmaceuticals Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Teva Pharmaceutical Industries Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Takeda Pharmaceutical Company Limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Abbott Laboratories
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Novartis International AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Alkermes plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 AbbVie Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
8.2.17 Merck & Co. Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.17.2 Business Overview
-
8.2.17.3 Financials (Subject to data availability)
-
8.2.17.4 Product Types Specification
-
8.2.17.5 Business Strategy
-
8.2.17.6 S.W.O.TAnalysis
-
-
8.2.18 Mylan N.V.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.18.2 Business Overview
-
8.2.18.3 Financials (Subject to data availability)
-
8.2.18.4 Product Types Specification
-
8.2.18.5 Business Strategy
-
8.2.18.6 S.W.O.TAnalysis
-
-
8.2.19 Neurocrine Biosciences Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.19.2 Business Overview
-
8.2.19.3 Financials (Subject to data availability)
-
8.2.19.4 Product Types Specification
-
8.2.19.5 Business Strategy
-
8.2.19.6 S.W.O.TAnalysis
-
-
8.2.20 Vanda Pharmaceuticals Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.20.2 Business Overview
-
8.2.20.3 Financials (Subject to data availability)
-
8.2.20.4 Product Types Specification
-
8.2.20.5 Business Strategy
-
8.2.20.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Drug Class Analysis 2019 -2031, will provide market size split by Drug Class. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Drug Class Analysis 2019 -2031
-
10.1 Mood Stabilizer
-
10.1.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Mood Stabilizer 2019 -2031
-
-
10.2 Anticonvulsants
-
10.2.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Anticonvulsants 2019 -2031
-
-
10.3 Anti-Psychotic Drugs
-
10.3.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Anti-Psychotic Drugs 2019 -2031
-
-
10.4 Anti-Depressant Drugs
-
10.4.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Anti-Depressant Drugs 2019 -2031
-
-
10.5 Anti-Anxiety Drugs
-
10.5.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Anti-Anxiety Drugs 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Distribution Channel Analysis 2019 -2031
-
11.1 Hospital Pharmacies
-
11.1.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Hospital Pharmacies 2019 - 2031
-
-
11.2 Retail Pharmacies
-
11.2.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Retail Pharmacies 2019 - 2031
-
-
11.3 Online Pharmacies
-
11.3.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Online Pharmacies 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Bipolar Disorder Analysis 2019 -2031
-
12.1 Bipolar I Disorder
-
12.1.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Bipolar I Disorder 2019 -2031
-
-
12.2 Bipolar II Disorder
-
12.2.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Bipolar II Disorder 2019 -2031
-
-
12.3 Cyclothymic Disorder
-
12.3.1 Global Bipolar Disorders and Treatment Revenue Market Size and Share by Cyclothymic Disorder 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Bipolar Disorders and Treatment market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Bipolar Disorders and Treatment Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Bipolar Disorders and Treatment Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Bipolar Disorders and Treatment Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Bipolar Disorders and Treatment Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Bipolar Disorders and Treatment Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Bipolar Disorders and Treatment Market
Key Questions Answered By Bipolar Disorders and Treatment Market Report 2024
| Why Mood Stabilizer have a significant impact on Bipolar Disorders and Treatment market? |
| What are the key factors affecting the Mood Stabilizer and Anticonvulsants of Bipolar Disorders and Treatment Market? |
| What is the CAGR/Growth Rate of Hospital Pharmacies during the forecast period? |
| By type, which segment accounted for largest share of the global Bipolar Disorders and Treatment Market? |
| Which region is expected to dominate the global Bipolar Disorders and Treatment Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
